GlassScriptPhysician profile
Mary Ann Cameron
NPI 1619924677
$5,234.50
in general payments reported to CMS, 2019-2025
36 companies · $758 in 2025
The $758 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $627 · 2021: $943 · 2022: $622 · 2023: $869 · 2024: $637 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,214.32 | 2019-2024 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $492.95 | 2019-2025 | |
| Amgen INC. | $470.79 | 2019-2025 | Tavneos, Krystexxa |
| Daiichi Sankyo INC. | $400.95 | 2020-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $359.76 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $267.10 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $202.66 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $182.60 | 2019-2023 | Veltassa |
| Mallinckrodt Hospital Products INC. | $158.86 | 2020-2025 | Terlivaz |
| Horizon Therapeutics Plc | $157.19 | 2019-2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $151.64 | 2019 | |
| Opko Pharmaceuticals, LLC | $136.51 | 2020-2024 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $120.51 | 2019-2021 | |
| Glaxosmithkline, LLC. | $89.46 | 2022-2024 | Benlysta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $76.40 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $64.34 | 2019 | |
| Fresenius USA Marketing, INC. | $61.52 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.24 | 2024-2025 | Jardiance |
| Veloxis Pharmaceuticals, INC. | $56.79 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $53.68 | 2024-2025 | Tarpeyo |
| Cycle Pharmaceuticals INC | $51.88 | 2025 | Venxxiva |
| Akebia Therapeutics INC | $46.59 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $43.54 | 2022-2023 | Purified Cortrophin Gel |
| Novo Nordisk INC | $40.85 | 2022-2023 | |
| Pharmacosmos Therapeutics INC. | $32.80 | 2023 | Monoferric |
| Shield Therapeutics INC | $31.90 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.77 | 2021 | |
| Angiodynamics, INC. | $24.37 | 2021 | |
| Biogen, INC. | $24.29 | 2023 | Skyclarys |
| Strongbridge US INC. | $23.82 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $20.32 | 2021 | |
| Mallinckrodt Enterprises LLC | $20.04 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.42 | 2022 | |
| Aurinia Pharma U.S., INC. | $16.44 | 2022 | |
| Medtronic, INC. | $15.83 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ann Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.